Administer’s profitability in Q1 improved more than expected, and our 2024E EBITDA estimate is up by...
Etteplan was able to improve its profitability during the first quarter as was expected.
Redeye provides a research update following the Q1 report published by Initiator Pharma earlier toda...
Redeye updates its view of Nanexa following the Q1 report and recent events in the company, includin...
Redeye sees a quarter well in line with our estimates, and we believe that the quarterly reports wil...
Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved r...
Redeye updates on Invisio following its Q1-results which were in line with our expectations.
InfraCom’s Q1 2024 report was mixed with net sales below Redeye Research estimates (RRe), while bett...
Ferronordic will report its Q1 results on 16 May. Taken together, we expect another challenging quar...
Relais' Q1 adjusted EBITA came in 13% above LSEG Data & Analytics consensus with a strong 12% y/y or...
Redeye remains positive towards Avensia following a Q1 report largely matching our forecasts.
Redeye sustains its positive view of CombinedX following a solid Q1 report.
80% of the ATH order book to be delivered within 12 months Higher opex to cut EBIT by 5-7% in 2024e-...
Redeye in this note comments Neonode’s Q1’24 and the last major news around the Aequitas lawsuit.
Q1 report due Wednesday 15 May at 07:00 CEST Q1e: sales EUR 44.
MGI’s Q124 report shows an impressive 21% organic revenue uplift over Q123, with both good new clien...
Today, Advenica recieved its third order for this quarter of SEK8.
En investering i Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) ger exponering...
Redeye provides a note following NeoDynamics’ Q1 2024 report.
Redeye provides an update on Scandinavian ChemoTech following the strong Q1 2024 report.